|
See related Navelbine Oral/IV information |
|
|
|
Manufacturer |
Pierre Fabre Medicament |
|
Distributor |
Hong Kong: Orient Europharma |
|
Contents |
Vinorelbine ditartrate |
|
Indications |
Non-small cell lung cancer. Metastatic breast cancer. |
|
Dosage |
Oral Monotherapy: 60 mg/m2 BSA once a wk for the 1st 3 doses, may be increased to 80 mg/m2 once a wk after the 3rd dose. Combination: 60 mg/m2 days 1 & 8 cycle 1, 80 mg/m2 days 1 & 8 thereafter every 3 wk. IV Non-small cell lung cancer & advanced breast cancer Monotherapy: 25-30 mg/m2 once wkly. Combination: 25-30 mg/m2 days 1 & 8 every 3 wk. |
|
Administration |
Should be taken with food (Take at the end of a meal. Swallow whole, do not chew/suck.). |
|
Contraindications |
Known hypersensitivity to vinorelbine or other vinca alkaloids. Neutrophil count <1,500/mm3 or severe infection current or recent (w/in 2 wk). Combination w/ yellow fever vaccine. Pregnancy & lactation. Oral: GI disorder, history of extensive surgical resection of stomach or small intestine, severe hepatic insufficiency, fructose intolerance. |
|
Special Precautions |
Monitor hematological parameters during treatment. Infection, ischemic cardiac disease. Delay treatment if neutrophil count is <1,500/mm3 &/or platelet count is <75,000/mm3. Oral: Renal insufficiency, radiotherapy. |
|
Adverse Drug Reactions |
Neutropenia, anemia, thrombocytopenia, nausea & vomiting, constipation & paralytic ileus, stomatitis & diarrhea, alopecia, fatigue, fever, arthralgia including jaw pain, myalgia, pain at tumor site. Oral: Anorexia, esophagitis, ataxia, neuromotor disorders. Rarely, ischemic heart disease, cutaneous reactions. Transient hepatic enzyme elevation. IV: Loss of tendon reflexes, weakness of lower extremities, dyspnea & bronchospasm, erythema, burning pain, vein discoloration & local phlebitis, pain at different locations.
View ADR Monitoring Form |
|
Drug Interactions |
Oral anticoagulants. Oral: Contraindicated w/ yellow fever vaccine. Phenytoin, fosphenytoin, live attenuated vaccine, ciclosporin, tacrolimus, itraconazole, mitomycin. IV: CYP3A4 inducers or inhibitors.
View more drug interactions with Navelbine Oral/IV |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
ATC Classification |
L01CA04 - vinorelbine ; Belongs to the class of plant alkaloids and other natural products, vinca alkaloids and analogues. Used in the treatment of cancer. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Navelbine Oral/IV soft capsule |
|
Navelbine Oral/IV 20 mg x 1's |
|
Navelbine Oral/IV 30 mg x 1's |
|
|
Navelbine Oral/IV injection |
|
Navelbine Oral/IV 10 mg/1 mL x 1 mL x 10's |
|
Navelbine Oral/IV 50 mg/5 mL x 5 mL x 10's |
|
|
|
Manufacturer: |
Pierre Fabre Medicament |
|
Distributor: |
Hong Kong: Orient Europharma |
|
|
|
